Smruthi

Maaran Review: Barring Dhanush and, to an extent Smruthi Venkat, the actors have little to do in film. Malavika Mohanan gets the worst deal.

In a filing to the BSE, the company said European Directorate for Quality of Medicines (EDQM) and the US Food and Drug Administration (USFDA) have inspected its active pharmaceutical ingredients site from October 14-18, 2013.

A man who strangled to death his younger college lecturer sister at her residence for defying her family and marrying a lower caste person has been arrested.

Smruthi Organics Ltd has informed BSE that the members at the Annual General Meeting (AGM) of the Company held on July 27, 2011, inter alia, have accorded to the following: 1. Adoption of audited balance sheet and prom and loss a/c for the year ended March 31, 2011 along with all annexure and report of the directors and auditors thereon. 2. Declara...

Smruthi Organics Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 27, 2011, inter alia, to consider the following subjects: 1. To take on record the unaudited quarterly accounts of the Company for the quarter ended June 30, 2011. 2. Approval of contracts in which directors are interested.

Smruthi Organics Ltd has informed BSE that the Board of Directors of the Company at its meeting held on April 28, 2011, inter alia, has approved the following: 1. Recommendation of Dividend @ 25% on Equity Shares i.e. Rs. 2.50 per share. 2. Acceptance of resignation of Mr. E. Niranjan Rao and Mr. P. K. Kumaran from the Directorship of the Company.

Sales rise 100.69% to Rs 32.01 croreSmruthi Organics reported net profit of Rs 1.16 crore in the quarter ended March 2010 as against net loss of Rs 0.36 crore during the previous quarter ended March 2009. Sales rose 100.69% to Rs 32.01 crore in the quarter ended March 2010 as against Rs 15.95 crore during the previous quarter ended March 2009.For t...

Of 20%The board of Smruthi Organics in its meeting on 27 April 2010 has recommended dividend at the rate of 20% for the financial year 2009-2010.

Sales rise 58.48% to Rs 31.76 croreNet profit of Smruthi Organics rose 94.25% to Rs 1.69 crore in the quarter ended September 2009 as against Rs 0.87 crore during the previous quarter ended September 2008. Sales rose 58.48% to Rs 31.76 crore in the quarter ended September 2009 as against Rs 20.04 crore during the previous quarter ended September 20...

The board of Smruthi Organics has recommended dividend at the rate of 10% for the financial year 2008-09.This was recommended at the board meeting held on 30 July 2009.

Net profit of Smruthi Organics declined 36.36% to Rs 0.56 crore in the quarter ended June 2009 as against Rs 0.88 crore during the previous quarter ended June 2008. Sales rose 31.65% to Rs 23.21 crore in the quarter ended June 2009 as against Rs 17.63 crore during the previous quarter ended June 2008. ParticularsQuarter Ended Jun. 2009Jun. 2008% V...

The board meeting of Smruthi Organics will be held on 30 July 2009 To take on record the unaudited quarterly accounts of the company for the quarter ended 30 June 2009.The board meeting will also be held to recommend dividend and to consider and adopt the audited statements of accounts for the year ended 31 March 2009.

The members of Smruthi Organics have approved the issue of 50 lakhs non-convertible cumulative redeemable preference shares to the promoters.This was approved at the extraordinary general meeting held on 21 May 2009.

Smruthi Organics has announced that the company's product 'Amlodipine Besilate (API)' has been granted certificate of suitability (COS) by European Directorate from the Quality of Medicines and Healthcare (EDQM). This recognition shall immensely help the company to enter EU regulatory business in EU countries.The company made this announcement duri...

Smruthi Organics has announced that the company's product 'Amlodipine Besilate (API)' has been granted certificate of suitability (COS) by European Directorate from the Quality of Medicines and Healthcare (EDQM). This recognition shall immensely help the company to enter EU regulatory business in EU countries.The company made this announcement duri...

Maaran Review: Barring Dhanush and, to an extent Smruthi Venkat, the actors have little to do in film. Malavika Mohanan gets the worst deal.

In a filing to the BSE, the company said European Directorate for Quality of Medicines (EDQM) and the US Food and Drug Administration (USFDA) have inspected its active pharmaceutical ingredients site from October 14-18, 2013.

A man who strangled to death his younger college lecturer sister at her residence for defying her family and marrying a lower caste person has been arrested.

Smruthi Organics Ltd has informed BSE that the members at the Annual General Meeting (AGM) of the Company held on July 27, 2011, inter alia, have accorded to the following: 1. Adoption of audited balance sheet and prom and loss a/c for the year ended March 31, 2011 along with all annexure and report of the directors and auditors thereon. 2. Declara...

Smruthi Organics Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 27, 2011, inter alia, to consider the following subjects: 1. To take on record the unaudited quarterly accounts of the Company for the quarter ended June 30, 2011. 2. Approval of contracts in which directors are interested.

Smruthi Organics Ltd has informed BSE that the Board of Directors of the Company at its meeting held on April 28, 2011, inter alia, has approved the following: 1. Recommendation of Dividend @ 25% on Equity Shares i.e. Rs. 2.50 per share. 2. Acceptance of resignation of Mr. E. Niranjan Rao and Mr. P. K. Kumaran from the Directorship of the Company.

Sales rise 100.69% to Rs 32.01 croreSmruthi Organics reported net profit of Rs 1.16 crore in the quarter ended March 2010 as against net loss of Rs 0.36 crore during the previous quarter ended March 2009. Sales rose 100.69% to Rs 32.01 crore in the quarter ended March 2010 as against Rs 15.95 crore during the previous quarter ended March 2009.For t...

Of 20%The board of Smruthi Organics in its meeting on 27 April 2010 has recommended dividend at the rate of 20% for the financial year 2009-2010.

Sales rise 58.48% to Rs 31.76 croreNet profit of Smruthi Organics rose 94.25% to Rs 1.69 crore in the quarter ended September 2009 as against Rs 0.87 crore during the previous quarter ended September 2008. Sales rose 58.48% to Rs 31.76 crore in the quarter ended September 2009 as against Rs 20.04 crore during the previous quarter ended September 20...

The board of Smruthi Organics has recommended dividend at the rate of 10% for the financial year 2008-09.This was recommended at the board meeting held on 30 July 2009.

Net profit of Smruthi Organics declined 36.36% to Rs 0.56 crore in the quarter ended June 2009 as against Rs 0.88 crore during the previous quarter ended June 2008. Sales rose 31.65% to Rs 23.21 crore in the quarter ended June 2009 as against Rs 17.63 crore during the previous quarter ended June 2008. ParticularsQuarter Ended Jun. 2009Jun. 2008% V...

The board meeting of Smruthi Organics will be held on 30 July 2009 To take on record the unaudited quarterly accounts of the company for the quarter ended 30 June 2009.The board meeting will also be held to recommend dividend and to consider and adopt the audited statements of accounts for the year ended 31 March 2009.

The members of Smruthi Organics have approved the issue of 50 lakhs non-convertible cumulative redeemable preference shares to the promoters.This was approved at the extraordinary general meeting held on 21 May 2009.

Smruthi Organics has announced that the company's product 'Amlodipine Besilate (API)' has been granted certificate of suitability (COS) by European Directorate from the Quality of Medicines and Healthcare (EDQM). This recognition shall immensely help the company to enter EU regulatory business in EU countries.The company made this announcement duri...

Smruthi Organics has announced that the company's product 'Amlodipine Besilate (API)' has been granted certificate of suitability (COS) by European Directorate from the Quality of Medicines and Healthcare (EDQM). This recognition shall immensely help the company to enter EU regulatory business in EU countries.The company made this announcement duri...